Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M372Revenue $M12.0Net Margin (%)-6.8Z-Score3.5
Enterprise Value $M326EPS $-2.9Operating Margin %8.0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-6.8Higher ROA y-yY
Price/Book5.710-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsN
Price/Sales3.95-y EBITDA Growth Rate %0Current Ratio4.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-6.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-19.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M42.9ROI % (ttm)-96.2Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SUPNRobert Bruce 2014-09-30 Add0.73%$7.99 - $11.13
($8.98)
$ 8.67-4%Add 300%400,000
SUPNRobert Bruce 2014-06-30 Buy 0.25%$7.32 - $10.85
($8.88)
$ 8.67-2%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SUPN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SUPN Robert Bruce 2014-09-30400,0000.930.97+300%
Premium Most recent portfolio changes are included for Premium Members only!


SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bhatt Padmanabh P.Sr. VP of IP; CSO 2013-08-19Sell2,285$8.215.6view
BIGHAM MICHAELDirector 2013-03-22Buy35,000$5.4160.26view
SIEBERT JOHN MDirector 2013-03-21Buy3,000$5.557.64view
Khattar Jack A.President, CEO 2013-03-15Buy10,000$6.1540.98view
PATRICK GREGORY SVP, CFO 2013-03-14Buy5,000$6.9524.75view
ORBIMED ADVISORS LLC10% Owner 2013-02-13Sell302,183$7.5514.83view
ORBIMED ADVISORS LLC10% Owner 2012-12-18Sell297,815$6.9225.29view
SIEBERT JOHN MDirector 2012-12-04Buy7,000$8.146.51view
Abingworth Management LTD10% Owner 2012-05-04Buy1,100,000$573.4view
ORBIMED ADVISORS LLCDirector, 10% Owner 2012-05-04Buy1,100,000$573.4view

Press Releases about SUPN :

    Quarterly/Annual Reports about SUPN:

    News about SUPN:

    Articles On GuruFocus.com
    Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
    Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 


    More From Other Websites
    Nasdaq stocks posting largest percentage increases Jan 28 2015
    Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog Jan 26 2015
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 23 2015
    Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents Jan 21 2015
    Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents Jan 21 2015
    Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Jan 20 2015
    Supernus Sues Par for Infringement of Trokendi XR(R) Patents Jan 16 2015
    Supernus Sues Par for Infringement of Trokendi XR(R) Patents Jan 16 2015
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 13 2015
    Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough Dec 15 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2014
    Supernus Faces another Patent Challenge for Oxtellar XR Dec 11 2014
    Supernus Faces New Patent Challenge for Trokendi XR Dec 10 2014
    Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R) Dec 10 2014
    Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R) Dec 10 2014
    Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Dec 09 2014
    Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Dec 09 2014
    Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? Dec 02 2014
    How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry Dec 01 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 25 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK